Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to combination therapy in hepatitis virus C genotype 2 and 3.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP - 1 Aug 2009

Khan Anwar Ahmed, Sarwar Shahid

Abstract excerpt

OBJECTIVE: To determine Sustained Viral Response (SVR) to Interferon (IFN) and ribavirin therapy in chronic hepatitis C patients of genotype 2 and 3. STUDY DESIGN: Case series. PLACE AND DURATION OF STUDY: The Garden Clinic, Lahore, from June 1997 to August 2007. METHODOLOGY: All patients of both genotypes 2 and 3 receiving combination therapy were included. Standard IFN with ribavirin was started in 648 (90%)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites
Share to Antiviral Agents
Share to Databases, Factual

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C, Chronic

Share to Interferons

Share to Ribavirin

Share to Treatment Outcome

Source

Identifiers

PMID: 19651007
DOI: 08.2009/JCPSP.473477

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to combination therapy in hepatitis virus C genotype 2 and 3.PMID 19651007Read ↗

The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil.Semantic proximity Read ↗

Treatment of genotype 2 and 3 chronic hepatitis C virus-infected patients.Semantic proximity Read ↗

Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3.Semantic proximity Read ↗

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.Semantic proximity Read ↗

Conventional interferon alfa-2b and ribavirin for 12 versus 24 weeks in HCV genotype 2 or 3.Semantic proximity Read ↗

Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis.Semantic proximity Read ↗

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.Semantic proximity Read ↗

Response rates to standard interferon treatment in HCV genotype 3a.Semantic proximity Read ↗

End treatment response and sustained viral response in hepatitis C virus genotype 3 among Pakistani population.Semantic proximity Read ↗

Efficacy of peginterferon alpha-2A and ribavirin combination therapy in treatment-naive Estonian patients with chronic hepatitis C.Semantic proximity Read ↗

Do differences exist between chronic hepatitis C genotypes 2 and 3?Semantic proximity Read ↗

Hepatitis C virus infection: Are there still specific problems with genotype 3?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.